Cerus is a biomedical products company focused on developing and commercializing the INTERCEPT Blood System for blood safety. The INTERCEPT Blood System, which is based on Co.'s technology for controlling biological replication, is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. Co.'s INTERCEPT Blood System is for use with blood components including plasma, platelets, and red blood cells. Co. has received U.S. Food and Drug Administration approval for the INTERCEPT Blood System for Cryoprecipitation, which uses Co.'s plasma system to produce Pathogen Reduced Cryoprecipitated Fibrinogen Complex for the treatment and control of bleeding. The CERS stock yearly return is shown above.
The yearly return on the CERS stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2016 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the CERS annual return calculation with any dividends reinvested as applicable (on ex-dates).
|